Fresenius Medical Care launches US kidney system: Fresenius Medical Care stock gains 1.09 percent

Published on 10/26/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA cleared the system October 19, 2026 for acute kidney injury care. Fresenius Medical Care stock costs EUR 40.90 on October 26, 2026, 1.09 percent above Xetra close.

Product launch and operating evidence

Fresenius Medical Care launched multiFiltratePRO in the United States on October 21, 2026.
Second-quarter revenue reached USD 5.55 billion versus USD 5.48 billion expected.
Fresenius Medical Care stock trades at EUR 40.90 at 10:01 a.m. CET at Lang & Schwarz on October 26, 2026, 1.09 percent above the Xetra close of October 23, 2026.

Pop-Art-Comicillustration einer Pflegekraft und eines Patienten in einer farbenfrohen Dialyseszene — Pop-Art-Comic zeigt farbenfrohe Dialyseszene mit Pflegekraft und Patient, inspiriert von Fresenius Medical Care AG DE0005785802, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) is trading at EUR 40.90 at Lang & Schwarz on October 26, 2026 at 10:01 a.m. CET, 1.09 percent above the Xetra close of October 23, 2026 at EUR 40.46. The company launched its multiFiltratePRO kidney replacement system in the United States on October 21, 2026, according to FT.com.

US launch adds a product catalyst

The launch targets critically ill patients with acute kidney injury and follows FDA clearance on October 19, 2026. The system integrates citrate and calcium pumps, while the accompanying solutions support continuous kidney replacement therapy for patients weighing at least 40 kilograms.

For investors, the commercial question is how quickly the controlled rollout can translate into products revenue. The company said the system will move toward full availability in the United States, while its existing portfolio already spans dialysis care, machines, dialyzers and related therapies.

What do the latest figures show?

Fresenius Medical Care's second-quarter revenue was USD 5.55 billion, compared with USD 5.48 billion expected, while earnings per share came to USD 0.66 versus a USD 0.62 consensus estimate, MarketBeat reported on October 20, 2026. Revenue therefore exceeded the forecast by USD 70.00 million, a 1.28 percent difference.

The recent chronology is clear. On October 7, 2026, Fresenius Medical Care announced Shervin J. Korangy as chief executive officer; on October 19, 2026, US regulators cleared one system and approved two dedicated solutions; on October 21, 2026, the company announced the US launch of multiFiltratePRO. The company investor page carries the leadership announcement and the product timeline.

Three dates shape the next steps

The next two scheduled dates are November 3, 2026, for the third-quarter financial results, and November 6, 2026, for the third-quarter financial report, according to the Fresenius Medical Care investor calendar.

Analyst caution remains visible

J.P. Morgan maintained a Sell rating and a EUR 32.30 target on October 23, 2026, according to MarketScreener. The target is EUR 8.60 below the Lang & Schwarz price, so the product launch is arriving alongside a clearly cautious analyst view.

Stock trades above the Xetra close

The FMC share was trading at EUR 40.90 at Lang & Schwarz on October 26, 2026 at 10:01 a.m. CET, 1.09 percent above the Xetra close of October 23, 2026 at EUR 40.46. The price reaction gives the launch context, while the November reporting dates provide the next fundamental test.

The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.